In a longitudinal study of more than 9000 patients, most did not undergo testing for mutations in homologous recombination repair genes. Testing for mutations in homologous recombination repair (HRR) ...
A minority of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States undergo genetic testing for homologous recombination repair (HRR) mutations, despite the ...
Credit: Getty Images In the US, the proportion of men receiving HRR testing peaked at 55.5% in 2020 and decreased to 49.4% in 2022. From 2014-2022, only about 38% of men with metastatic ...
Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US). This is an ...
Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with ...
SEOUL, South Korea, June 8, 2023 /PRNewswire/ -- IMBdx Inc., a premier precision cancer diagnostic company accredited by CAP, announced today its plans to broaden its collaboration with AstraZeneca, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback